ANN ARBOR — A new, simple, non-invasive test that predicts risk for cardiovascular disease is to be made available by Gulf & Word Traders throughout the United Arab Emirates and neighboring countries.
Everist Genomics Inc., Ann Arbor, developer of the test, announced today that they have appointed Gulf & World Traders as exclusive agents of the technology in the region.
“We are delighted to be partnering with a well-established and respected organization that has the capacity to serve the market and make our breakthrough technology widely available,” says Everist Genomics CEO, Steve Everist.
“Cardiovascular disease is a major life threat in the Gulf region as it is in many other countries of the world, and we believe that this new heart health predictor will be a valuable asset in identifying people who are at risk so that they, together with their physicians, can take the appropriate measures to lower their risk of heart attack or stroke,” says Nabil Emil, general manager.
The medical device, known as AngioDefender, determines vascular health status by measuring the ability of patient’s arteries to naturally expand in response to changes within the body, known as endothelial function. Endothelial function is a known indicator of atherosclerosis and coronary heart disease and has also been linked to risk for dementia. Previously, the only reliable methods for testing proper endothelial function requires special equipment and training to perform and are not readily available. AngioDefender’s patented technology solves this problem with a simple, reliable, and fast test that is remarkably easy to administer. Using the device, patients will know immediately if they are at low, medium, or high risk for cardiovascular disease.
“The beauty of this test is that it can identify those who are at risk for cardiovascular disease even though they may currently have no obvious symptoms such as high blood pressure or poor cholesterol levels,” says Everist.